THE LATEST NEWS IN CANCER CLINICAL RESEARCH

DESTINY-BREAST03 results establish T-DXd as the standard of care for 2L metastatic breast cancer

Pembrolizumab may be the new standard of care for RCC with intermediate to high risk of recurrence

Spotlight: PATHFINDER Breast cancer trial

Ipilimumab-nivolumab combo as 2L does not improve survival for immunotherapy naive NSCLC

COVID-19 Pandemic created a cancer screening deficit in the United States

Apalutamide plus ADT improves overall survival in metastatic castration-sensitive prostate cancer

Up to 30% of patients with metastatic breast cancer develop brain disease

We explore new ways to treat breast cancer with brain metastases

Announcing clinical trial with talazoparib for hormone-sensitive metastatic prostate cancer

Adjuvant olaparib reduces recurrence and metastatic progression in patients with early breast cancer

Chemotherapy de-escalation: outstanding advances in the treatment of breast cancer

The Pandemic Offers lessons to Speed up Management of Future Clinical Trials in Oncology

CAILA: New Clinical Trial for Breast Cancer

Joining forces with QUADRAM Institute Bioscience and University of Bristol for the project CALADRIO

Presentation at ESMO Breast Cancer 2021: METALLICA Trial in Progress

ORPHEUS Study: Evaluation of Retifanlimab In Penile Cancer

Results of the KELLY trial

Cancer Network presents MEDSIR’s study Phergain-2

PECATI: New clinical trial with pembrolizumab and lenvatinib for patients with advanced thymic tumor

PHERGain-2: a study of a new therapeutic strategy to avoid chemotherapy in breast cancer patients